指南与共识神经免疫神经肌肉病

国际共识指南:重症肌无力管理(2020更新版)

International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
指南 / 共识 · Neurology · 2020-11-03

该指南由美国重症肌无力基金会任命的国际专家组基于最新文献对2016版共识进行更新,采用RAND/UCLA适宜性方法就7个治疗主题形成推荐,更新了胸腺切除术推荐,并新增利妥昔单抗、依库珠单抗、甲氨蝶呤及眼肌型MG早期免疫抑制和免疫检查点抑制剂相关MG的共识推荐。

要点

  • 更新了胸腺切除术的推荐。
  • 新增利妥昔单抗、依库珠单抗和甲氨蝶呤的使用推荐。
  • 新增眼肌型MG早期免疫抑制及免疫检查点抑制剂相关MG的推荐。

核心结论

  • 该国际专家共识指南基于新证据更新,为全球临床医生管理重症肌无力患者提供推荐。

研究设计与样本

  • 采用RAND/UCLA适宜性方法就7个治疗主题制定共识推荐。
  • 2019年2月国际小组重新召集并增加1名代表南美的成员。
  • 对所有既往推荐进行时效性审查,并基于近期文献就需纳入或更新的主题制定新共识推荐。
  • 采用最多3轮匿名电子邮件投票达成共识,轮间根据小组意见修改推荐。

主要发现

  • 更新了既往胸腺切除术的推荐。
  • 新增利妥昔单抗、依库珠单抗和甲氨蝶呤使用的推荐。
  • 新增眼肌型MG早期免疫抑制及免疫检查点抑制剂治疗相关MG的推荐。

关键数值与推荐

  • 采用简单多数投票(80%小组成员投「yes」)批准语法和句法的小改动以提高清晰度。

临床怎么用

  • 临床医生可依据该更新共识管理重症肌无力,包括胸腺切除术、利妥昔单抗、依库珠单抗、甲氨蝶呤及特殊情形(眼肌型MG早期免疫抑制、免疫检查点抑制剂相关MG)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting "yes") was used to approve minor changes in grammar and syntax to improve clarity. RESULTS: The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment. CONCLUSION: This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2020. PMID: 33144515. doi:10.1212/WNL.0000000000011124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。